Dr Andrew Nierenberg (Keynote speaker)

Thomas P. Hackett MD Endowed Chair in Psychiatry at Massachusetts General Hospital, Director, Dauten Family Center for Bipolar Treatment Innovation, Professor of Psychiatry, Harvard Medical School

Dr. Nierenberg’s primary interests are bipolar depression and novel treatments. He lectures extensively, both nationally and internationally, teaches, supervises, maintains an active clinical practice, consults to industry, and conducts clinical trials funded by federal, foundation, industry, and philanthropic sources. He serves as a peer reviewer for over 35 psychiatric journals. He is a member of the editorial boards of over 15 journals including the Journal of Clinical Psychiatry, Journal of Clinical Psychopharmacology, Journal of Affective Disorders, Australian New Zealand Journal of Psychiatry, and Bipolar Disorders and is the associate editor of Psychiatric Annals.

Dr. Nierenberg attended the Albert Einstein College of Medicine of Yeshiva University and went on to a residency in psychiatry at New York University/Bellevue Hospital and then became a Robert Wood Johnson Clinical Scholar at Yale University.Dr. Nierenberg then joined the faculty at Harvard Medical School, first at McLean Hospital in Belmont, Massachusetts and then at Massachusetts General Hospital, where he holds his current positions. He is also Honorary Professor in the School of Medicine, Faculty of Health at Deakin University, Geelong Australia.

Dr Lakshmi Yatham (Keynote speaker)

 

Associate Head of Research and of Research and International Affairs, Department of Psychiatry, University of British Columbia, Canada.

Dr Yatham’s major areas of research interest include neurobiology and treatment of bipolar disorder and major depression. Dr. Yatham leads a Canadian consortium on bipolar disorder, which is currently pursuing testing of new treatments for bipolar disorder using pragmatic and controlled trials with substantial funding from CIHR.

Dr. Yatham co-led the development of Canadian guidelines for treatment of bipolar disorder in 1997 and his group recently revised the guidelines for 2005 and these were published with International Commentaries in Bipolar Disorders Journal in June. He is Chair of the bipolar group of the Canadian Network for Mood and Anxiety Treatments (CANMAT), and is actively involved at a national and international level in continuing medical education and public education on diagnosis and treatment of bipolar disorder for psychiatrists, family physicians, and the general public. Dr. Yatham is currently the President for the International Society for Bipolar Disorders and he is on the editorial boards of a number of journals including Bipolar Disorders, Brain Pharmacology, Human Psychopharmacology, Quarterly Journal of Mental Health etc. He has published over 140 papers in peer-reviewed international journals and presented his research work at numerous international conferences

 

Dr George Papakostas (Keynote speaker)

Scientific Director of the Massachusetts General Hospital, Clinical Trials Network and Institute, Director of treatment-resistant depression studies in the Department of Psychiatry at MGH, and Associate Professor of Psychiatry at Harvard Medical School.

Dr Papakostas also Director of a Harvard-wide course on the design and conduct of clinical trials in medicine. The focus of Dr. Papakostas’ research includes the pharmacotherapy of major depressive disorder, including treatment-resistant depression; the study of the placebo effect and its relevance to clinical trial design in mood and anxiety disorders; and the study of clinical and biologic predictors, moderators, and mediators of treatment outcome in major depressive disorder. Dr. Papakostas is co-principal investigator of the RAPID Network, the NIMH-funded series of studies of novel, rapidly acting antidepressant therapies.

Professor Shitij Kapur (National speaker)

Professor of Psychiatry and Dean, Faculty of Medicine, Dentistry and Health Sciences, Assistant Vice Chancellor (Health), University of Melbourne,

Professor Kapur was previously the Executive Dean of the Institute of Psychiatry, Psychology & Neuroscience, and Assistant Principal (Academic Performance) at King’s College London. He is a clinician-scientist with expertise in psychiatry, neuroscience and brain imaging. He trained as a Psychiatrist at the University of Pittsburgh, and undertook a PhD and Fellowship at the University of Toronto. He is a Diplomate of the American Board of Psychiatry and Neurology, similarly Board Certified in Canada and has a specialist medical license in the United Kingdom.

Professor  Kapur’s main research interest is in understanding Schizophrenia and its treatment. He has used brain imaging, animals models and clinical studies which have led to a better understanding of antipsychotic action, its relationship to brain dopamine receptor blockade, the role of appropriate dosing of these drugs and has led to the development of the ‘salience’ framework of psychosis and the ‘early onset’ hypothesis if antipsychotic action. He is now working on how ‘biomarkers’ might be best incorporated into psychiatric care and drug development.